Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-08-22
2006-08-22
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C536S023400, C536S023720, C536S023100, C435S236000, C435S069200, C435S069300, C435S069400, C435S235100, C424S204100, C424S205100, C424S199100, C424S185100, C424S186100, C424S202100, C514S002600
Reexamination Certificate
active
07094411
ABSTRACT:
Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
REFERENCES:
patent: 4810492 (1989-03-01), Fujita et al.
patent: 5021347 (1991-06-01), Yasui et al.
patent: 5229293 (1993-07-01), Matsuura et al.
patent: 5494671 (1996-02-01), Lai et al.
patent: 5514375 (1996-05-01), Paoletti et al.
patent: 6165477 (2000-12-01), Ivy et al.
patent: 6184024 (2001-02-01), Lai et al.
patent: 5276941 (1993-10-01), None
patent: WO 90/01946 (1990-03-01), None
patent: WO 92/03545 (1992-03-01), None
patent: WO 93/06214 (1993-01-01), None
patent: WO 9640933 (1996-12-01), None
patent: WO 98/37911 (1998-09-01), None
patent: WO 99/63095 (1999-12-01), None
patent: WO 02/072036 (2002-09-01), None
Aberle et al., “A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms.”J. Immunl.163:6756-6761 (1999).
Allison et al., “Synthesis and Secretion of Recombinant Tick-Borne Encephalitis Virus Protein E in Soluble and Particulate Form.”J. Virol.69(9): 5816-5820 (Sep. 1995).
Alvarez et al. “A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients.”Hum. Gene Ther.8:229-242 (Jan. 20, 1997).
Anderson et al., “Isolation of West Nile Virus from Mosquitoes, Crows, and a Cooper's Hawk in Connecticut.”Science286:2331-2333 (Dec. 17, 1999).
Arroyo et al., “Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE).”J. Virol.75(2):934-942 (Jan. 2001).
Asnis et al., “The West Nile Virus Outbreak of 1999 in New York: The Flushing Hospital Experience.”Clin. Infect. Dis.30: 413-418 (2000).
Azevedo et al., “Main features of DNA-based immunization vectors.”Braz. J. Med. Biol. Res.32(2):147-153 (1999).
Bhamarapravati et al., “Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers.”Bull World Health Organ.65(2):189-195 (1987).
Bhamarapravati and Yoksan., “Study Of Bivalent Dengue Vaccine In Volunteers.”Lancet1:1077 (1989).
Bhamarapravati and Yoksan. “Live attenuated tetravalent vaccine,”In Dengue and Dengue Hemorrhagic Fever, D. J. Gubler and G. Kuno (ed.),. Cab International, Wallingford, OX, UK p. 367-377 (1997).
Bhamarapravati and Sutee. “Live attenuated tetravalent dengue vaccine.” Vaccine 18:44-47 (2000).
Bhatt et al., “Growth Characteristics of the Chimeric Japanese Encephalitis Virus Vaccine Candidate, ChimeriVax-JE (YF/JE SA14-14-2), InCulex tritaeniorhynchus, Aedes albopictus, and Aedes aegyptiMosquitoes.”Am. J. Trop. Med. Hyg.62(4):480-484 (2000).
Blok et al., “Comparison of a Dengue-2 Virus and Its Candidate Vaccine Derivative. Sequence Relationships with the Flaviviruses and Other Viruses.”Virology187:573-590 (1992).
Bray et al., “Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins with or without Nonstructural Protein NS1 Are Protected against Fatal Dengue Virus Encephalitis.”J. Virol.63(6): 2853-2856 (Jun. 1989).
Bray et al., “Monkeys Immunized with Intertypic Chemeric Dengue Viruses Are Protected against Wild-Type Virus Challenge.”J. Virol.70(6):4162-4166 (Jun. 1996).
Bray and Lai., “Construction of intertypic chimeric dengue viruses by substitution of structural protein genes.”Proc. Natl. Acad. Sci. USA88:10342-10346 (Nov. 1991).
Butpret et al., “Attentuation Markers of a Candidate Degue Type 2 Vaccine Virus, Strain 16681 (PDK-53), Are Defined by Mutations in the 5′ Noncoding Region and Nonstructural Proteins 1 and 3.”J. Virol.74(7):3011-3019 (Apr. 2000).
Butrapet et al., “Chimeric Dengue Type 2/Type 1 Viruses Induce Immune Responses In Cynomolgus Monkeys.”Southeast Asian J. Trop. Med. Public Health33(3):589-599 (Sep. 2002).
Cahour et al., “Growth-Restricted Dengue Virus Mutants Containing Deletions in the 5′ Noncoding Region of the RNA Genome.”Virology207:68-76 (1995).
Chambers et al., “Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties.”J. Virol.73(4):3095-3101 (Apr. 1999).
Chambers et al., “Flavivirus Genome Organization, Expression, and Replication.”Annu. Rev. Microbiol.44:649-688 (1990).
Chambers et al., “Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse Model.”J. Virol.77(6):3655-3668 (Mar. 2003).
Chang et al., “A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice.”J. Virol.74(9):4244-4252 (May 2000).
Chen et al., “Construction of Intertypic Chimeric Dengue Viruses Exhibiting Type 3 Antigenicity and Neurovirulence for Mice.”J. Virol.69(8):5186-5190 (Aug. 1995).
Clarke and Casals. “Techniques For Hemagglutination And Hemagglutination-Inhibition With Arthropod-Borne Viruses.”Am. J. Trop. Med. Hyg.7:561-573 (1958).
Davis et al., “West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses in Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-linked Immunosorbent Assays.”J. Virol.75(9):4040-4047 (May 2001).
Deubel et al., “Nucleotide Sequence and Deduced Amino Acid Sequence of the Nonstructural Proteins of Dengue Type 2 Virus, Jamaica Genotype: Comparative Analysis of the Full-Length Genome.”Virology165:234-244 (1988).
Deubel et al., “Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Type 2 Virus, Jamaica Genotype.”Virology155:365-377 (1986).
Dharakul et al., “Dengue Virus-Specific Memory T Cell Responses in Human Volunteers Receiving a Live Attenuated Dengue Virus Type 2 Candidate Vaccine.”J. Infect. Dis.170:27-33 (1994).
Dmitriev et al., “Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis.”J. Biotechnol.44:97-103 (1996).
Duarte dos Santos et al., “Complete nucleotide sequences of yellow fever virus vaccine strains 17DD and 17D-213.”Virus Res.35:35-41 (1995).
Durbin et al., “Attenuation And Immunogenicity In Humans Of A Live Dengue Virus Type-4 Vaccine Candidate With A 30 Nucleotide Detection In Its 3′-Untranslated Region.”Am. J. Trop. Med. Hyg.65(5):405-413 (2001).
Falgout et al., “Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NS1 Protects against Lethal Dengue Virus Encephalitis.”J. Virol.64(9):4356-4363 (Sep. 1990).
Falgout et al., “Proper Processing of Dengue Virus Nonstructural Glycoprotein NS1 Requires the N-terminal Hydrophobic Signal Sequence and the Downstream Nonstructural Protein NS2a.”J. Virol.63(5):1852-1860 (May 1989).
Garmendia et al., “Recovery and Identification of West Nile Virus from a Hawk in Winter.”J. Cli
Bhamarapravati Natth
Butrapet Siritorn
Gubler Duane J.
Kinney Claire Y. H.
Kinney Richard M.
Housel James
Li Bao Qun
Needle & Rosenberg P.C.
The United States of America as represented by the Department of
LandOfFree
Avirulent, immunogenic flavivirus chimeras does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Avirulent, immunogenic flavivirus chimeras, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Avirulent, immunogenic flavivirus chimeras will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3610556